Evidence map›Paper›PMID 29554272›Full record

ArticleInflammatory bowel diseases2018

The Artificial Sweetener Splenda Promotes Gut Proteobacteria, Dysbiosis, and Myeloperoxidase Reactivity in Crohn's Disease-Like Ileitis.

Alexander Rodriguez-Palacios, Andrew Harding, Paola Menghini, Catherine Himmelman, Mauricio Retuerto, Kourtney P Nickerson, Minh Lam, Colleen M Croniger, Mairi H McLean, Scott K Durum and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Inflammatory bowel diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
130citing papers in PubMed, 6 pooled it
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

130 citing papers in PubMed, 6 syntheses or guidelines pooled it, 219 citations in OpenAlex.

  1. Roles of the gut microbiome in weight management.Nature reviews. Microbiology · 2023
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Global and Historical Distribution ofFrontiers in medicine · 2020
    Pooled it
  6. Pooled it
  7. Trial
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

70 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 2 countries.

Alexander Rodriguez-PalaciosDivision of Gastroenterology and Liver Disease, Department of Medicine, School of Medicine, Cleveland, Ohio.
Andrew HardingDivision of Gastroenterology and Liver Disease, Department of Medicine, School of Medicine, Cleveland, Ohio.
Paola MenghiniDivision of Gastroenterology and Liver Disease, Department of Medicine, School of Medicine, Cleveland, Ohio.
Catherine HimmelmanDivision of Gastroenterology and Liver Disease, Department of Medicine, School of Medicine, Cleveland, Ohio.
Mauricio RetuertoCenter for Medical Mycology, Department of Dermatology, School of Medicine, Cleveland, Ohio.
Kourtney P NickersonDepartment of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio.
Minh LamDivision of Gastroenterology and Liver Disease, Department of Medicine, School of Medicine, Cleveland, Ohio.
Colleen M CronigerDepartment of Nutrition, School of Medicine, Cleveland, Ohio.
Mairi H McLeanCancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland.
Scott K DurumCancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland.
Theresa T PizarroDepartment of Pathology, Case Western Reserve University, School of Medicine, Cleveland, Ohio.
Mahmoud A GhannoumCenter for Medical Mycology, Department of Dermatology, School of Medicine, Cleveland, Ohio.
Sanja IlicDepartment of Human Sciences and Human Nutrition, The Ohio State University, Columbus, Ohio.
Christine McDonaldDepartment of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio.
Fabio CominelliDivision of Gastroenterology and Liver Disease, Department of Medicine, School of Medicine, Cleveland, Ohio.
Cleveland Clinic Lerner College of Medicine · USCase Western Reserve University · USCenter for Cancer Research · USNational Cancer Institute · USThe Ohio State University · USUniversity Hospitals of Cleveland · USUniversity School · US

Funding

Ubiquitination Pathways Mediating Chronic Intestinal InflammationP01DK091222 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI RODRIGUEZ-PALACIOS, ALEXANDER · 2011 to 2020
$16.5M
The Cleveland Digestive Diseases Research Core Center (DDRCC)P30DK097948 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI AMITABH CHAK · 2015 to 2026
$15.6M
Chronic Inflammation and CarcinogenesisZIABC011150 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI DURUM, SCOTT · 2009 to 2025
$8.5M
MECHANISMS OF EXPERIMENTAL CROHNS DISEASER01DK055812 · NIDDK · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI COMINELLI, FABIO · 1999 to 2019
$4.9M
CYTOKINES AND INFLAMMATORY BOWEL DISEASER01DK042191 · NIDDK · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI COMINELLI, FABIO, PIZARRO, THERESA TORRES · 1995 to 2022
$4.7M
CYTOKINES AND INFLAMMATORY BOWEL DISEASER37DK042191 · NIDDK · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI COMINELLI, FABIO · 1999 to 2009
$3.8M
Autophagy and Nod2 Function in Crohn's DiseaseR01DK082437 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI MCDONALD, CHRISTINE L · 2009 to 2013
$1.6M
Cytokines and Inflammatory Bowel DiseaseR56DK042191 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI COMINELLI, FABIO · 2010 to 2010
$504k
Spinning Disk Confocoal MicroscopeS10RR026820 · NCRR · CLEVELAND CLINIC LERNER COM-CWRU · PI DRAZBA, JUDY · 2010 to 2010
$500k
Mechanisms of Experimental Crohn's DiseaseR56DK055812 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI COMINELLI, FABIO, RODRIGUEZ-PALACIOS, ALEXANDER · 2021 to 2021
$403k
NCRR NIH HHS S10 RR026820NIDDK NIH HHS P01 DK091222NIDDK NIH HHS P30 DK097948NIDDK NIH HHS R01 DK042191NIDDK NIH HHS R01 DK055812NIDDK NIH HHS R01 DK082437NIDDK NIH HHS R37 DK042191NIDDK NIH HHS R56 DK042191NIDDK NIH HHS R56 DK055812
6 · The paper itself

Abstract

Background: Epidemiological studies indicate that the use of artificial sweeteners doubles the risk for Crohn's disease (CD). Herein, we experimentally quantified the impact of 6-week supplementation with a commercial sweetener (Splenda; ingredients sucralose maltodextrin, 1:99, w/w) on both the severity of CD-like ileitis and the intestinal microbiome alterations using SAMP1/YitFc (SAMP) mice. Methods: Metagenomic shotgun DNA sequencing was first used to characterize the microbiome of ileitis-prone SAMP mice. Then, 16S rRNA microbiome sequencing, quantitative polymerase chain reaction, fluorescent in situ hybridization (FISH), bacterial culture, stereomicroscopy, histology, and myeloperoxidase (MPO) activity analyses were then implemented to compare the microbiome and ileitis phenotype in SAMP with that of control ileitis-free AKR/J mice after Splenda supplementation. Results: Metagenomics indicated that SAMP mice have a gut microbial phenotype rich in Bacteroidetes, and experiments showed that Helicobacteraceae did not have an exacerbating effect on ileitis. Splenda did not increase the severity of (stereomicroscopic/histological) ileitis; however, biochemically, ileal MPO activity was increased in SAMP treated with Splenda compared with nonsupplemented mice (P < 0.022) and healthy AKR mice. Splenda promoted dysbiosis with expansion of Proteobacteria in all mice, and E. coli overgrowth with increased bacterial infiltration into the ileal lamina propria of SAMP mice. FISH showed increase malX gene-carrying bacterial clusters in the ilea of supplemented SAMP (but not AKR) mice. Conclusions: Splenda promoted gut Proteobacteria, dysbiosis, and biochemical MPO reactivity in a spontaneous model of (Bacteroidetes-rich) ileal CD. Our results indicate that although Splenda may promote parallel microbiome alterations in CD-prone and healthy hosts, this did not result in elevated MPO levels in healthy mice, only CD-prone mice. The consumption of sucralose/maltodextrin-containing foods might exacerbate MPO intestinal reactivity only in individuals with a pro-inflammatory predisposition, such as CD.

Indexed as

AnimalsBacteroidetesCrohn DiseaseDisease Models, AnimalDysbiosisFemaleHumansIleitisIn Situ Hybridization, FluorescenceIntestinal MucosaMaleMiceMice, Inbred AKRMicrobiotaPeroxidaseProteobacteriaPeroxidaseRNA, Ribosomal, 16SSucroseSweetening Agentstrichlorosucrose

Identifiers

PMID29554272
PMCPMC5950546
OpenAlexW2792385423

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.